Author + information
Cardiac hypertrophy leading to heart failure becomes one of the major causes of morbidity and mortality in the world. So how to delay or block the process of cardiac hypertrophy is an important project in the prevention of heart failure. Pyrroloquinoline quinone (PQQ) as a new type of vitamins has been found to have extensive biological activity. showed to effectively reduce the risk of cardiovascular disease. The aim of this study was to determine whether PQQ can effectively inhibit isoproterenol (ISO)-induced cardiac hypertrophy.
Cardiomyocytes were pretreated by PBS or PQQ with the final concentration of 5, 10, 20 μM for 3 hours, and then were induced by 10 μM ISO for 48 h. Cell surface areas were measured by cell immunofluorescence. mRNA transcription and protein levels of ANP, BNP, and β-MHC were measured by real-time PCR and western blot analysis. The levels of intracellular reactive oxygen species (ROS) after Iso and PQQ treatment were measured by ROS Assay Kit.
Surface areas of cardiomyocytes induced by Iso increased by 50% compared to the control group, but PQQ pre-treatment could effectively prevent the Iso-induced cell hypertrophy. The mRNA levels and the protein expressions of ANP, BNP and β-MHC in cardiomyocytes with PQQ pre-treatment were obviously reduced, comparing to the Iso group. Moreover PQQ produced a dose-dependent reduction in the degree of hypertrophy. ROS level was increased by Iso induction, while pre-treatment of PQQ made ROS return to basal level as the control.
This study mainly discovers that PQQ can block ISO-induced cardiomyocyte hypertrophy by scavenging intracellular oxygen free radicals.